Lexicon Pharmaceuticals, Inc.
LXRX · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $14 | $29 | $1 | $27 |
| % Growth | -50.9% | 2,187.3% | -95.2% | – |
| Cost of Goods Sold | $0 | $0 | $0 | $26 |
| Gross Profit | $14 | $29 | $1 | $1 |
| % Margin | 99.9% | 99.3% | 97.6% | 2.3% |
| R&D Expenses | $19 | $16 | $15 | $27 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $8 | $9 | $12 | $0 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $7 |
| Operating Expenses | $26 | $25 | $27 | $33 |
| Operating Income | -$12 | $4 | -$26 | -$33 |
| % Margin | -85.9% | 12.9% | -2,034.8% | -123.3% |
| Other Income/Exp. Net | -$1 | -$0 | $0 | -$1 |
| Pre-Tax Income | -$13 | $3 | -$25 | -$34 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$13 | $3 | -$25 | -$34 |
| % Margin | -90% | 11.3% | -2,004.4% | -127.2% |
| EPS | -0.04 | 0.009 | -0.07 | -0.09 |
| % Growth | -544.4% | 112.9% | 22.2% | – |
| EPS Diluted | -0.04 | 0.009 | -0.07 | -0.09 |
| Weighted Avg Shares Out | 363 | 363 | 362 | 361 |
| Weighted Avg Shares Out Dil | 363 | 364 | 362 | 361 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $2 | $2 | $3 |
| Interest Expense | $2 | $2 | $2 | $4 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$10 | $6 | -$23 | -$20 |
| % Margin | -73.8% | 19.9% | -1,845% | -76.5% |